MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-09-2026
OraSure Technologies Net Debt 2011-2026 | OSUR
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt OraSure Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -197 M | -266 M | -289 M | -81.7 M | -113 M | - | -68.5 M | -88.4 M | -71 M | -108 M | -94.1 M | -92.9 M | -93.2 M | -87.9 M | -16.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -16.6 M | -289 M | -119 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical instruments industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
-45 M | - | - | $ 810 M |  USA |
 |
Luminex Corporation
LMNX
|
-106 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-517 K | - | -9.52 % | $ 20.6 M | USA |
 |
Alcon
ALC
|
2.46 B | $ 75.8 | -0.08 % | $ 40.4 B |  Schweiz |
 |
Ekso Bionics Holdings
EKSO
|
-581 K | $ 10.99 | 1.48 % | $ 26.7 M | USA |
 |
The Cooper Companies
COO
|
2.38 B | $ 64.42 | -0.82 % | $ 12.8 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
-12.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
781 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
66.8 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
1.58 B | - | -0.05 % | $ 10.3 B | USA |
 |
iRhythm Technologies
IRTC
|
-154 M | $ 122.35 | 0.73 % | $ 3.92 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
-411 M | - | -0.02 % | $ 16.3 B | USA |
 |
Repro Med Systems
KRMD
|
-8.38 M | $ 3.96 | -0.75 % | $ 183 M | USA |
 |
Haemonetics Corporation
HAE
|
623 M | $ 59.93 | 0.52 % | $ 3.02 B | USA |
 |
electroCore
ECOR
|
-53 K | $ 6.18 | -0.08 % | $ 52.4 K | USA |
 |
ICU Medical
ICUI
|
972 M | $ 124.82 | 0.22 % | $ 3.08 B | USA |
 |
Envista Holdings Corporation
NVST
|
276 M | $ 26.8 | -0.89 % | $ 4.5 B | USA |
 |
Microbot Medical
MBOT
|
-3.05 M | $ 2.2 | 0.92 % | $ 101 M |  Israel |
 |
Isoray
ISR
|
-28.4 M | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
-3.2 B | $ 482.22 | 0.71 % | $ 172 B | USA |
 |
Glaukos Corporation
GKOS
|
-21.6 M | $ 121.48 | 0.5 % | $ 5.88 B | USA |
 |
Masimo Corporation
MASI
|
572 M | $ 178.63 | -0.04 % | $ 9.52 B | USA |
 |
Milestone Scientific
MLSS
|
-955 K | $ 0.32 | -1.27 % | $ 26.3 M | USA |
 |
InfuSystem Holdings
INFU
|
33.3 M | $ 10.34 | 0.68 % | $ 214 M | USA |
 |
Merit Medical Systems
MMSI
|
299 M | $ 68.58 | -0.04 % | $ 4.06 B | USA |
 |
Pulse Biosciences
PLSE
|
-73.2 M | $ 23.02 | -5.07 % | $ 1.55 B | USA |
 |
Retractable Technologies
RVP
|
-1.69 M | $ 0.65 | 0.2 % | $ 19.5 M | USA |
 |
Pro-Dex
PDEX
|
15 M | $ 52.1 | 2.24 % | $ 171 M | USA |
 |
LeMaitre Vascular
LMAT
|
143 M | $ 113.45 | 0.49 % | $ 2.57 B | USA |
 |
Predictive Oncology
POAI
|
-9.23 M | - | - | $ 31.1 M | USA |
 |
STAAR Surgical Company
STAA
|
-115 M | $ 25.67 | 3.34 % | $ 1.27 B | USA |
 |
STERIS plc
STE
|
1.78 B | $ 221.8 | -0.77 % | $ 21.9 B | USA |
 |
BioLife Solutions
BLFS
|
-88.9 M | $ 21.38 | -1.57 % | $ 985 M | USA |
 |
Stereotaxis
STXS
|
-7.98 M | $ 1.93 | -1.53 % | $ 176 M | USA |
 |
Baxter International
BAX
|
7.55 B | $ 18.16 | -1.39 % | $ 9.32 B | USA |
 |
ResMed
RMD
|
513 M | $ 219.85 | 0.15 % | $ 32.1 B | USA |
 |
Teleflex Incorporated
TFX
|
2.26 B | $ 136.56 | -0.07 % | $ 6.09 B | USA |
 |
AtriCure
ATRC
|
-104 M | $ 29.28 | 3.79 % | $ 1.4 B | USA |
 |
Harvard Bioscience
HBIO
|
27.8 M | $ 6.86 | 1.18 % | $ 305 M | USA |
 |
Utah Medical Products
UTMD
|
-60.6 M | $ 67.17 | -1.03 % | $ 218 M | USA |
 |
NeuroMetrix
NURO
|
-1.49 M | - | 5.05 % | $ 9.02 M | USA |
 |
West Pharmaceutical Services
WST
|
-566 M | $ 306.16 | -1.14 % | $ 22.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.74 B | $ 11.91 | 0.08 % | $ 2.37 B | USA |
 |
AngioDynamics
ANGO
|
-48.3 M | $ 11.1 | -0.89 % | $ 453 M | USA |
 |
Becton, Dickinson and Company
BDX
|
17.1 B | $ 152.14 | -1.74 % | $ 43.8 B | USA |
 |
Nephros
NEPH
|
-2.48 M | $ 2.87 | 1.06 % | $ 29.8 M | USA |
 |
Repligen Corporation
RGEN
|
-236 M | $ 117.6 | 3.1 % | $ 6.55 M | USA |